Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of zanubrutinib + bendamustine + rituximab in previously untreated advanced follicular lymphoma
ChiCTR2500095617Phase 2Recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Jan 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of zanubrutinib, bendamustine and rituximab in follicular lymphoma (FL), sponsored by Sun Yat-sen University Cancer Center. Primary endpoint: Complete response rate. Started Jan 2025; status: recruiting.
02
Drugs
zanubrutinibbendamustinerituximab
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on ChiCTR2500095617.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500095617.